{"name":"Neuraltus Pharmaceuticals","permalink":"neuraltus-pharmaceuticals","crunchbase_url":"http://www.crunchbase.com/company/neuraltus-pharmaceuticals","homepage_url":"http://www.neuraltus.com/","blog_url":"","blog_feed_url":"","twitter_username":"","category_code":"biotech","number_of_employees":null,"founded_year":null,"founded_month":null,"founded_day":null,"deadpooled_year":null,"deadpooled_month":null,"deadpooled_day":null,"deadpooled_url":null,"tag_list":"","alias_list":"","email_address":"npinfo@neuraltus.com","phone_number":"(650) 424-1600 ","description":"","created_at":"Wed Feb 01 02:19:20 UTC 2012","updated_at":"Wed Feb 01 02:19:20 UTC 2012","overview":"<p>Neuraltus Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases. Neuraltus has three clinical-stage programs in its development pipeline, including potential treatments for Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig&#8217;s disease), Parkinson&#8217;s disease and dyskinesias associated with the treatment of Parkinson&#8217;s disease, Alzheimer&#8217;s disease, and Multiple Sclerosis, as well as lysosomal storage disorders such as Fabry&#8217;s disease and Gaucher&#8217;s disease. Each of Neuraltus&#8217; clinical-stage programs is advancing novel drug molecules that represent new, first-in-class approaches to treating the Company&#8217;s target disease indications.</p>\n\n<p>Neuraltus began operations in 2009 based on a broadly enabling technology portfolio and intellectual property assembled by the company founders, Ari Azhir, PhD, Neuraltus&#8217; Chief Operating Officer; Michael McGrath, MD, PhD, Professor of Laboratory Medicine at the University of California, San Francisco; and Edgar Engleman, MD, Professor of Medicine and Pathology at Stanford University School of Medicine. In March 2009 Neuraltus closed a $17M Series A financing with leading venture groups Latterell Venture Partners, VantagePoint Venture Partners and Adams Street Partners</p>","image":{"available_sizes":[[[100,98],"assets/images/resized/0017/2416/172416v1-max-150x150.png"],[[100,98],"assets/images/resized/0017/2416/172416v1-max-250x250.png"],[[100,98],"assets/images/resized/0017/2416/172416v1-max-450x450.png"]],"attribution":null},"products":[],"relationships":[{"is_past":false,"title":"President and CEO","person":{"first_name":"Andrew","last_name":"Gengos","permalink":"andrew-gengos","image":null}}],"competitions":[],"providerships":[],"total_money_raised":"$26.6M","funding_rounds":[{"round_code":"a","source_url":"http://www.neuraltus.com/pages/news_rel03_26_09.html","source_description":"Neuraltus Pharmaceuticals Raises $17 Million Series A Funding ","raised_amount":17000000,"raised_currency_code":"USD","funded_year":2009,"funded_month":3,"funded_day":26,"investments":[{"company":null,"financial_org":{"name":"Latterell Venture Partners","permalink":"latterell-venture-partners","image":{"available_sizes":[[[150,21],"assets/images/resized/0005/5132/55132v2-max-150x150.png"],[[250,36],"assets/images/resized/0005/5132/55132v2-max-250x250.png"],[[287,42],"assets/images/resized/0005/5132/55132v2-max-450x450.png"]],"attribution":null}},"person":null},{"company":null,"financial_org":{"name":"VantagePoint Venture Partners","permalink":"vantagepoint-venture-partners-2","image":null},"person":null},{"company":null,"financial_org":{"name":"Adams Street Partners","permalink":"adams-street-partners","image":{"available_sizes":[[[150,48],"assets/images/resized/0001/4352/14352v1-max-150x150.png"],[[185,60],"assets/images/resized/0001/4352/14352v1-max-250x250.png"],[[185,60],"assets/images/resized/0001/4352/14352v1-max-450x450.png"]],"attribution":null}},"person":null}]},{"round_code":"b","source_url":"http://onbiovc.com/neuraltus-pharmaceuticals-inc-series-b-96m/","source_description":"Neuraltus Pharmaceuticals, Inc.: Series B $9.6M","raised_amount":9600000,"raised_currency_code":"USD","funded_year":2012,"funded_month":1,"funded_day":31,"investments":[{"company":null,"financial_org":{"name":"Latterell Venture Partners","permalink":"latterell-venture-partners","image":{"available_sizes":[[[150,21],"assets/images/resized/0005/5132/55132v2-max-150x150.png"],[[250,36],"assets/images/resized/0005/5132/55132v2-max-250x250.png"],[[287,42],"assets/images/resized/0005/5132/55132v2-max-450x450.png"]],"attribution":null}},"person":null},{"company":null,"financial_org":{"name":"VantagePoint Venture Partners","permalink":"vantagepoint-venture-partners-2","image":null},"person":null},{"company":null,"financial_org":{"name":"Adams Street Partners","permalink":"adams-street-partners","image":{"available_sizes":[[[150,48],"assets/images/resized/0001/4352/14352v1-max-150x150.png"],[[185,60],"assets/images/resized/0001/4352/14352v1-max-250x250.png"],[[185,60],"assets/images/resized/0001/4352/14352v1-max-450x450.png"]],"attribution":null}},"person":null}]}],"investments":[],"acquisition":null,"acquisitions":[],"offices":[{"description":"","address1":"2483 E. Bayshore Road","address2":"Suite 212 ","zip_code":"94303 ","city":"Palo Alto","state_code":"CA","country_code":"USA","latitude":null,"longitude":null}],"milestones":[],"ipo":null,"video_embeds":[],"screenshots":[],"external_links":[]}